Small, preclinical studies on breast tissue suggest the pill mifepristone shows promise for reducing the risk of breast cancer, however the use of mifepristone for medical abortion has created barriers for developing it for other purposes. This finding is highlighted in a Viewpoint published in The Lancet Obstetrics, Gynecology, & Women’s Health.
This article was originally published on MedicalXpress.com